Physician profile
Dina Oster
NPI 1518071356
$3,056.04
in general payments reported to CMS, 2019-2025
26 companies · $386 in 2025
The $386 reported for 2025 was more than what 87% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $156 · 2021: $100 · 2022: $567 · 2023: $452 · 2024: $906 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $513.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $452.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $423.59 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $255.43 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $219.62 | 2019-2025 | |
| Lilly USA, LLC | $151.28 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Merck Sharp & Dohme LLC | $145.14 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $98.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $98.55 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $83.01 | 2022-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.87 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2024-2025 | |
| Dynavax Technologies Corporation | $61.72 | 2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $55.05 | 2024 | |
| Shield Therapeutics INC | $54.14 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.56 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.63 | 2021 | |
| Boston Scientific Corporation | $32.79 | 2023 | Wavewriter Alpha Prime 16, Spaceoar Vue System - 10ml |
| Topcon Healthcare Solutions, INC. | $32.53 | 2019 | |
| Amarin Pharma, INC. | $27.99 | 2020-2021 | |
| Corcept Therapeutics | $22.42 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $19.27 | 2025 | Nexletol |
| Astellas Pharma US INC | $18.21 | 2024 | Veozah |
| Genentech USA, INC. | $15.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Oster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.